This is a study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug, Vorinostat (the U.S. Adopted Name for suberoylanilide hydroxamic acid or MK0683), in the treatment of advanced malignant pleural mesothelioma.

Ages eligible for study:  18 years and above
Genders eligible for study:  male and female

Inclusion Criteria:

• Patient must be 18 years or older with a confirmed diagnosis of malignant pleural mesothelioma.
• Patient must have failed prior chemotherapy that included pemetrexed with either cisplatin or carboplatin.
• Patient must have adequate bone marrow and liver and kidney function.
• Patient must be capable of self-care and out of bed for more than 50% of waking hours.
• Patient must have ability to swallow pills.

Exclusion Criteria:

• Patient has been treated with another investigational agent that has similar properties.
• Patient has an active infection within 2 weeks of the start of study drug, or had treatment with intravenous antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drug.
• Patient is pregnant or breast feeding.